UniProt functional annotation for Q12178



	UniProt functional annotation for Q12178

UniProt code: Q12178.

Organism: Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast).

Taxonomy: Eukaryota; Fungi; Dikarya; Ascomycota; Saccharomycotina; Saccharomycetes; Saccharomycetales; Saccharomycetaceae; Saccharomyces.

Function: Catalyzes the hydrolytic deamination of cytosine to uracil or 5-methylcytosine to thymine. Is involved in the pyrimidine salvage pathway, which allows the cell to utilize cytosine for pyrimidine nucleotide synthesis. {ECO:0000269|PubMed:10501935, ECO:0000269|PubMed:9000374}.

Catalytic activity: Reaction=cytosine + H(+) + H2O = NH4(+) + uracil; Xref=Rhea:RHEA:20605, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:16040, ChEBI:CHEBI:17568, ChEBI:CHEBI:28938; EC=3.5.4.1; Evidence={ECO:0000269|PubMed:9000374};

Cofactor: Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000269|PubMed:12637534, ECO:0000269|PubMed:12906827, ECO:0000269|PubMed:15879217};

Biophysicochemical properties: Kinetic parameters: KM=1.1 mM for cytosine {ECO:0000269|PubMed:15823054}; KM=0.16 mM for 5-fluorocytosine {ECO:0000269|PubMed:15823054}; Note=kcat is 91 sec(-1) with cytosine as substrate and 17 sec(-1) with 5-fluorocytosine as substrate. {ECO:0000269|PubMed:15823054};

Pathway: Pyrimidine metabolism; UMP biosynthesis via salvage pathway; uracil from cytosine: step 1/1. {ECO:0000269|PubMed:10501935, ECO:0000305|PubMed:10501935}.

Subunit: Homodimer. {ECO:0000269|PubMed:12906827}.

Subcellular location: Cytoplasm {ECO:0000269|PubMed:14562095}. Nucleus {ECO:0000269|PubMed:14562095}.

Biotechnology: Also catalyzes the conversion of 5-fluorocytosine (5FC) to 5-fluorouracil (5FU); this activity allows the formation of a cytotoxic chemotherapeutic agent from a non-cytotoxic precursor. yCD/5FC is one of the most widely used enzyme/prodrug combinations for gene-directed enzyme prodrug therapy (GDEPT) for the treatment of cancers. 5FU is an anticancer drug used to treat breast, colon, rectal, stomach, and pancreatic cancers, and is the drug of choice for treating colorectal carcinoma. However, the drug has high gastrointestinal and hematological toxicities. In contrast, the prodrug 5FC is fairly non- toxic to human, because of the lack of CD activity in human cells. By producing 5FU in the tumor, the CD/5FC system minimizes the undesired toxic effects of 5FU. {ECO:0000305|PubMed:15823054}.

Miscellaneous: Present with 5180 molecules/cell in log phase SD medium. {ECO:0000269|PubMed:14562106}.

Similarity: Belongs to the cytidine and deoxycytidylate deaminase family. {ECO:0000305}.

Annotations taken from UniProtKB at the EBI.


Organism:		Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast).
Taxonomy:		Eukaryota; Fungi; Dikarya; Ascomycota; Saccharomycotina; Saccharomycetes; Saccharomycetales; Saccharomycetaceae; Saccharomyces.



Function:		Catalyzes the hydrolytic deamination of cytosine to uracil or 5-methylcytosine to thymine. Is involved in the pyrimidine salvage pathway, which allows the cell to utilize cytosine for pyrimidine nucleotide synthesis. {ECO:0000269\|PubMed:10501935, ECO:0000269\|PubMed:9000374}.


Catalytic activity:		Reaction=cytosine + H(+) + H2O = NH4(+) + uracil; Xref=Rhea:RHEA:20605, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:16040, ChEBI:CHEBI:17568, ChEBI:CHEBI:28938; EC=3.5.4.1; Evidence={ECO:0000269\|PubMed:9000374};
Cofactor:		Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000269\|PubMed:12637534, ECO:0000269\|PubMed:12906827, ECO:0000269\|PubMed:15879217};
Biophysicochemical properties:		Kinetic parameters: KM=1.1 mM for cytosine {ECO:0000269\|PubMed:15823054}; KM=0.16 mM for 5-fluorocytosine {ECO:0000269\|PubMed:15823054}; Note=kcat is 91 sec(-1) with cytosine as substrate and 17 sec(-1) with 5-fluorocytosine as substrate. {ECO:0000269\|PubMed:15823054};
Pathway:		Pyrimidine metabolism; UMP biosynthesis via salvage pathway; uracil from cytosine: step 1/1. {ECO:0000269\|PubMed:10501935, ECO:0000305\|PubMed:10501935}.
Subunit:		Homodimer. {ECO:0000269\|PubMed:12906827}.
Subcellular location:		Cytoplasm {ECO:0000269\|PubMed:14562095}. Nucleus {ECO:0000269\|PubMed:14562095}.
Biotechnology:		Also catalyzes the conversion of 5-fluorocytosine (5FC) to 5-fluorouracil (5FU); this activity allows the formation of a cytotoxic chemotherapeutic agent from a non-cytotoxic precursor. yCD/5FC is one of the most widely used enzyme/prodrug combinations for gene-directed enzyme prodrug therapy (GDEPT) for the treatment of cancers. 5FU is an anticancer drug used to treat breast, colon, rectal, stomach, and pancreatic cancers, and is the drug of choice for treating colorectal carcinoma. However, the drug has high gastrointestinal and hematological toxicities. In contrast, the prodrug 5FC is fairly non- toxic to human, because of the lack of CD activity in human cells. By producing 5FU in the tumor, the CD/5FC system minimizes the undesired toxic effects of 5FU. {ECO:0000305\|PubMed:15823054}.
Miscellaneous:		Present with 5180 molecules/cell in log phase SD medium. {ECO:0000269\|PubMed:14562106}.
Similarity:		Belongs to the cytidine and deoxycytidylate deaminase family. {ECO:0000305}.